u/heart_rate_bump

and the HR signal on the glucagon-containing molecules is worth tracking properly rather than anecdotally. mine went up 7bpm on titration on a triple agonist and back down at maintenance.

which is presumably where the HR signal comes from. mine went up more on reta than on anything else and settled once i stopped escalating.

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Which trial, and which arm?

the 11bpm is the bit that would have worried me most. mine went up 7 on a normal escalation and settled at maintenance, and 11 on a fast one is consistent with that being escalation-driven.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

I would not read across from the obesity programmes. Different population, different endpoint, different question.

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Biopsy-confirmed population or imaging-selected?

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit

Disagreeing with this bit: that number comes from a different programme with a different population.

Stocked line or made to order — did they say?

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Storage guidance that names a temperature, a state and a duration reflects actual stability work. Generic guidance usually reflects a template.

Which phase and which arm are you quoting?

baseline before you start is worth more than any later panel

Not convinced. A purity figure without a stated method is not comparable to one that has a method attached.

Imaging-derived liver fat fraction is a surrogate.

Agreed — and the endpoint definitions are where the actual claim lives.

Sent an unusual compound to VendorInvestigate because nobody on this site had ever posted one. 97.9% against a claimed 97.0%.

Bought small on anything without a testing history here. That rule has never once cost me anything.

ApoB is the one worth adding if you only add one

Concentrations can differ between products and between pharmacies. Switching mid-titration means redoing the arithmetic rather than carrying the old unit count across.

the confidence interval is the finding, the point estimate is the headline

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Have you taken this to whoever ordered it?

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

heart rate is the thing people report watching

fasting state and time of day change more than people expect

lyophilised and stored cold is the default for a reason

SELECT was cardiovascular outcomes, not weight

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

phase 2 data only, and people quote it like it is a label

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

tier 3 waiting lists are measured in years, not months

ApoB counts atherogenic particles rather than the cholesterol they carry, which is why it can diverge from LDL-C and why it is the addition most worth

Adding the obvious one — take it to whoever ordered the panel. This board cannot read it for you.

Fasting or not, and what time of day?

catalogue depth is not the same as catalogue quality